305
Participants
Start Date
April 16, 2019
Primary Completion Date
October 7, 2019
Study Completion Date
October 11, 2019
SDP-4 Ophthalmic Solution (0.1%)
Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
SDP-4 Ophthalmic Solution (1.0%)
Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
SDP-4 Ophthalmic Solution (3.0%)
Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Vehicle
Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Wake Forest Health Network Ophthalmology- Oak Hollow, High Point
Coastal Research Associates, Roswell
Clayton Eye Clinical Research, LLC, Morrow
Shettle Eye Research, Largo
Eye Associates of Fort Myers, Fort Myers
West Coast Eye Institute, Lecanto
Hernando Eye Institute, Brooksville
Nashville Vision Associates, Nashville
Total Eye Care, Memphis
Eye Specialty Group, Memphis
Abrams Eye Center, Cleveland
Drs. Quinn, Foster & Associates, Athens
Comprehensive Eye Care Ltd, Washington
Ophthalmology Associates, St Louis
Heart of America Eye Care, P.A., Shawnee Mission
Kannarr Eye Care, Pittsburg
Medical Center Ophth Assoc / Keystone Research, San Antonio
Texan Eye / Keystone Research, Ltd., Austin
North Valley Eye Medical Group, Mission Hills
Canyon City Eyecare, Azusa
LoBue Laser and Eye Medical Center, Murrieta
Eye Research Foundation, Newport Beach
Orange County Ophthalmology Medical Group, Garden Grove
North Bay Eye Associates, Petaluma
Grutzmacher & Lewis, A Medical Corporation DBA Sacramento Eye Consultants, Sacramento
Danbury Eye Physicians and Surgeons, PC, Danbury
Silk Technologies, Ltd.
INDUSTRY